Back to Ask the Diabetes Team Ask the Diabetes Team

From New York, USA:

If C-Peptide can be normal or close to it during the honeymoon period and antibodies are positive in type 1 patients only 60 to 80% of the time (as per your other answers on similar questions), what is the gold standard to know what type a patient has? I've been insulin dependent since diagnosis at the age of 19 and my doctor seems to be taking a "wait and see" approach. I want to know if there is any reason I shouldn't be able to try oral medications. Also, are there any studies about the your chances of dying in your sleep from a low?


Most patients can be classified as either type 1 or type 2 diabetes along clinical lines. The laboratory tests, including C-Peptide and the antibodies are helpful in cases where there is not a clear indication as to the type of diabetes present. At age 19, I would think you have type 1 diabetes, unless there are other factors not mentioned. In order to use oral medications in a patient with a history of type 1 diabetes, I would have to be very sure you did not have type 1 diabetes as the lack of insulin in patients with type 1 diabetes could lead to the development of diabetic ketoacidosis. As a physician, I would not want to commit a patient to a therapy that may put them at risk.


[Editor's comment: See our a web page on The Dead in Bed Syndrome. BH]

Original posting 4 Jan 2007
Posted to Diagnosis and Symptoms


  Home Return to Top

Last Updated: Tuesday April 06, 2010 15:10:10
This Internet site provides information of a general nature and is designed for educational purposes only. If you have any concerns about your own health or the health of your child, you should always consult with a physician or other health care professional.

This site is published by T-1 Today, Inc. (d/b/a Children with Diabetes), a 501c3 not-for-profit organization, which is responsible for its contents.
By using this site, you agree to our Terms of Use, Legal Notice, and Privacy Policy.
© Children with Diabetes, Inc. 1995-2015. Comments and Feedback.